Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo

These results demonstrate that the potency and specificity of sildenafil as an inhibitor of ABCB1 and ABCG2 is not sufficient to warrant further clinical testing of this agent in combination with anticancer drugs.